|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:access
|
gptkb:Robert_L._Smith
|
|
gptkbp:acquisition
|
gptkb:Celgene_Corporation
gptkb:Immunomedics
gptkb:Myokardia
|
|
gptkbp:advertising
|
gptkb:Jennifer_L._McCarthy
gptkb:Michael_J._McCarthy
gptkb:Linda_A._Hill
gptkb:William_A._Johnson
gptkb:James_A._McCarthy
gptkb:David_A._Smith
gptkb:Michael_A._Goldstein
|
|
gptkbp:CEO
|
gptkb:Linda_J._Johnson
gptkb:Susan_A._Smith
gptkb:David_L._Johnson
Giovanni Caforio
|
|
gptkbp:clinicalTrials
|
Phase 3 trials
ongoing studies
Phase 1 trials
Phase 2 trials
|
|
gptkbp:collaborations
|
gptkb:David_J._Johnson
|
|
gptkbp:customerService
|
gptkb:Patricia_A._Johnson
|
|
gptkbp:drugInterdiction
|
gptkb:Patricia_J._Smith
|
|
gptkbp:employees
|
30,000+
|
|
gptkbp:founded
|
1887
|
|
gptkbp:founder
|
gptkb:William_McLaren_Bristol
gptkb:John_Ripley_Myers
|
|
gptkbp:global_presence
|
gptkb:Robert_J._Smith
|
|
gptkbp:globalPresence
|
gptkb:Robert_A._Johnson
gptkb:Michael_L._Smith
gptkb:Patricia_L._Johnson
gptkb:Michael_J._Smith
gptkb:David_A._Smith
gptkb:Thomas_A._Smith
gptkb:Susan_J._Johnson
gptkb:Susan_A._Smith
gptkb:David_L._Johnson
gptkb:Patricia_J._Smith
gptkb:Thomas_J._Johnson
|
|
gptkbp:headOfMarketing
|
gptkb:Robert_J._Johnson
|
|
gptkbp:headquarters
|
gptkb:New_York_City
gptkb:United_States
|
|
gptkbp:healthcare
|
gptkb:Michael_L._Smith
gptkb:David_L._Johnson
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bristol-Myers Squibb Company, S.A.
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:innovation
|
gptkb:Thomas_J._Smith
|
|
gptkbp:internationalCooperation
|
gptkb:Susan_L._Johnson
|
|
gptkbp:manager
|
gptkb:David_A._Smith
gptkb:Patricia_A._Johnson
|
|
gptkbp:oversees
|
gptkb:Thomas_J._Johnson
|
|
gptkbp:partnerships
|
gptkb:AstraZeneca
gptkb:NantKwest
gptkb:Boehringer_Ingelheim
gptkb:Pfizer
gptkb:Regeneron_Pharmaceuticals
gptkb:Bristol-Myers_Squibb_Foundation
gptkb:Eli_Lilly_and_Company
gptkb:NantWorks
AbbVie
|
|
gptkbp:productionLocation
|
gptkb:Michael_A._Johnson
|
|
gptkbp:products
|
drugs
|
|
gptkbp:receives_funding_from
|
gptkb:Thomas_L._Smith
gptkb:Susan_L._Johnson
|
|
gptkbp:regulates
|
gptkb:Robert_J._Johnson
gptkb:Thomas_A._Smith
|
|
gptkbp:regulatoryCompliance
|
gptkb:Susan_L._Hockfield
|
|
gptkbp:research
|
gptkb:Thomas_C._Südhof
|
|
gptkbp:researchAndDevelopment
|
oncology
fibrosis
immunology
cardiovascular
|
|
gptkbp:revenue
|
$46.4 billion (2020)
|
|
gptkbp:stockExchange
|
gptkb:NYSE
|
|
gptkbp:stockSymbol
|
BMY
|
|
gptkbp:subsidiary
|
gptkb:Bristol-Myers_Squibb_Canada
gptkb:Bristol-Myers_Squibb_UK
gptkb:Bristol-Myers_Squibb_Australia
|
|
gptkbp:supplyChain
|
gptkb:Robert_A._Smith
|
|
gptkbp:sustainability
|
gptkb:Patricia_J._Johnson
|
|
gptkbp:tactics
|
gptkb:Michael_A._Johnson
|